Abstract
Abstract Objective: This phase II trial was performed to evaluate the efficacy and tolerability of tegafur/uracil (UFT) and oral leucovorin (LV) in elderly patients with advanced or metastatic colorectal cancer who had not received prior chemotherapy. Methods: Patients aged ≥70 years were eligible. UFT and LV were taken orally on days 1-28 of the cycle at doses of 300 mg/m2/day and 75 mg/body/day, respectively. Treatment was administered on an outpatient basis every 35 days and consisted of at least two cycles until disease progression. Results: A total of 30 patients were enrolled in this study. The median age of the patients was 81.5 years (range: 74-88 years). The observed overall response rate was 17.9%. The estimated median overall survival time was 23.5 months. Two patients (7%) experienced toxicities with a worst grade of 3, and one patient (4%) experienced toxicities with a worst grade of 4. There were no treatment-related deaths. No patients experienced grade 3 or 4 hematological adverse events. Conclusions: Although the response rate to UFT/LV was moderate, a favorable survival time and good tolerability were observed. UFT/LV can be one of the optional treatments for elderly colorectal cancer patients. Citation Format: Kohei Murata, Hirofumi Yamamoto, Mutsumi Fukunaga, Takeshi Kato, Tadashi Ohnishi, Yoshio Uemura, Hirofumi Ohta, Fumihiko Kimura, Masayuki Ohue, Riichiro Nezu, Mitsugu Sekimoto, Masataka Ikeda, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori, Clinical Study Group of Osaka University (CSGO), Colorectal Group. Phase II study of first line chemotherapy with tegafur/uracil and oral leucovorin in elderly patients with advanced or metastatic colorectal cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4682. doi:10.1158/1538-7445.AM2013-4682
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
